Researchers have made significant progress in understanding why chikungunya virus infections follow vastly different clinical trajectories, with some patients recovering within weeks while others face months or years of debilitating joint pain. New evidence points to genetic variations in immune response pathways as a primary determinant of disease progression. While the acute phase of chikungunya—characterized by high fever and joint swelling—typically resolves quickly, approximately 40% of patients develop chronic arthralgia that persists long after viral clearance. Scientists investigating human leukocyte antigen (HLA) polymorphisms and interferon signaling pathways have identified molecular differences that may explain these divergent outcomes. These findings are particularly timely as chikungunya transmission continues expanding globally, with cases now reported across 122 countries. Understanding the genetic basis of chronic infection could eventually lead to personalized treatment strategies and improved patient outcomes. Read the full article on GMJ Newsroom.
Was this article helpful?
